Fullerenol/iron nanocomposite diminishes doxorubicin-induced toxicity
- 26 Downloads
Fullerenol C60(OH)24 with its spherical shape, symmetrical structure, 1 nm size and the ability to form polyionic nanoparticles in water solution, was used to synthesise a novel nanocomposite made of fullerenol nanoparticles (FNP) and iron ions (Fe2+). The FNP/Fe2+ nanocomposite was characterised by DLS and TEM-EDS analyses which have shown that the size distribution of FNP/Fe2+ stayed in the same scope as the size distribution of FNP, ranging from 11 to 60 nm. However, Fe2+ did affect the change of FNP’s zeta potential (− 49.2 mV), shifting it to more positive values (− 30.8 mV). In this study, it was assumed that FNP/Fe2+ could reduce the toxic effects of doxorubicin (Dox). Male Wistar rats were treated i.p. with FNP/Fe2+ nanocomposite 1 h prior to Dox treatment. At the subcellular level, the ultrastructural analysis revealed minor alterations sporadically displayed within the heart and liver tissues. Moreover, at the molecular level, the gene expressions analysis of mRNAs for catalase (heart and liver) and MnSOD (only liver) were significantly downregulated, indicating reduction in oxidative stress. Overall, the pretreatment with FNP/Fe2+ nanocomposite, followed by Dox application, significantly diminished harmful effects of the applied drug on the heart and liver, suggesting the potential protective effect of the nanocomposite on the healthy tissues.
KeywordsFullerenol Iron Doxorubicin Nanocomposite qRTR-PCR Ultrastructural analysis Nanomedicine Health effects
This work has received a financial support from the Ministry of Education, Science and Technological Development, Republic of Serbia, Grant No. III 45005.We thank Professor Vladimir Srdic (Faculty of Technology, University of Novi Sad, Serbia) for DLS measurements and MSc Ivana Andjelkovic for technical support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Baimanov D, Cai R, Chen C (2019) Understanding the chemical nature of nanoparticle-protein interactions. Bioconjug ChemGoogle Scholar
- Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C (2002) Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 62:4592–4598Google Scholar
- Djordjevic A, Canadanovic-Brunet J, Vojinovic-Miloradov M, Bogdanovic G (2005) Antioxidant properties and hypothetical radical mechanism of fullerol C60(OH)24. Oxid Commun 27:806–812Google Scholar
- Djordjevic A, Ajdinović B, Dopudja M, Trajkovic S, Milovanovic Z, Maksin T, Neskovic O, Bogdanović VB, Trpkov Djordje T, Cveticanin J (2011) Scintigraphy of the domestic dog using [Tc-99m(CO)(3)(H2O)(3)]-C-60(OH)(22-24). Dig J Nanomater Biostructures 6(2011):99–106Google Scholar
- Djordjevic A, Srdjenovic B, Seke M, Petrovic D, Injac R, Mrdjanovic J (2015) Review of synthesis and antioxidant potential of fullerenol nanoparticles. J Nanomater 16:280Google Scholar
- Fonseca-Nunes, Ana, Paula Jakszyn, and Antonio Agudo. "Iron cancer risk-a systematic review and meta-analysis of the epidemiological evidence." Cancer epidemiology and prevention biomarkers 23 (2014): 12-31Google Scholar
- Injac R, Boskovic M, Perse M, Koprivec-Furlan E, Cerar A, Djordjevic A, Strukelj B (2008c) Acute doxorubicin nephrotoxicity in rats with malignant neoplasm can be successfully treated with fullerenolC60(OH)24 via suppression of oxidative stress. Pharmacol Rep 60:742Google Scholar
- Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422–8428Google Scholar
- Petrovic D, Seke M, Srdjenovic B, Djordjevic A (2015) Applications of anti/prooxidant fullerenes in nanomedicine along with fullerenes influence on the immune system. J Nanomater 16:279Google Scholar
- Sugino N, Telleria CM, Gibori G (1998) Differential regulation of copper-zinc superoxide dismutase and manganese superoxide dismutase in the rat corpus luteum: induction of manganese superoxide dismutase messenger ribonucleic acid by inflammatory cytokines. Biol Reprod 59:208–215CrossRefGoogle Scholar
- Theil, Elisabeth C.,Gunther L.Eichhorn, and Luigi G. Morzilli. "Iron bindingproteins without cofactors or sulfur clusters."" Advances in inorganic biochemistry 5 (1983): 1-38Google Scholar